25 XP   0   0   10

Altimmune Inc
Buy, Hold or Sell?

Let's analyse Altimmune together

PenkeI guess you are interested in Altimmune Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Altimmune Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Altimmune Inc

I send you an email if I find something interesting about Altimmune Inc.

Quick analysis of Altimmune (30 sec.)










What can you expect buying and holding a share of Altimmune? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€2.59
Expected worth in 1 year
€1.65
How sure are you?
41.2%

+ What do you gain per year?

Total Gains per Share
€-0.94
Return On Investment
-11.4%

For what price can you sell your share?

Current Price per Share
€8.28
Expected price per share
€3.961 - €15.99
How sure are you?
50%

1. Valuation of Altimmune (5 min.)




Live pricePrice per Share (EOD)

€8.28

Intrinsic Value Per Share

€-18.50 - €-21.71

Total Value Per Share

€-15.91 - €-19.13

2. Growth of Altimmune (5 min.)




Is Altimmune growing?

Current yearPrevious yearGrowGrow %
How rich?$150.4m$195.8m-$28.1m-16.8%

How much money is Altimmune making?

Current yearPrevious yearGrowGrow %
Making money-$19.6m-$21.7m$2.1m10.8%
Net Profit Margin-87,323.3%-372,146.3%--

How much money comes from the company's main activities?

3. Financial Health of Altimmune (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#315 / 1031

Most Revenue
#650 / 1031

Most Profit
#714 / 1031

Most Efficient
#1013 / 1031

What can you expect buying and holding a share of Altimmune? (5 min.)

Welcome investor! Altimmune's management wants to use your money to grow the business. In return you get a share of Altimmune.

What can you expect buying and holding a share of Altimmune?

First you should know what it really means to hold a share of Altimmune. And how you can make/lose money.

Speculation

The Price per Share of Altimmune is €8.28. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Altimmune.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Altimmune, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €2.59. Based on the TTM, the Book Value Change Per Share is €-0.24 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Altimmune.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.38-4.6%-0.35-4.2%-0.40-4.9%-0.33-3.9%-0.33-3.9%
Usd Book Value Change Per Share-0.32-3.9%-0.25-3.1%-0.02-0.2%0.162.0%0.162.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.32-3.9%-0.25-3.1%-0.02-0.2%0.162.0%0.162.0%
Usd Price Per Share2.54-6.55-9.84-8.00-8.00-
Price to Earnings Ratio-1.65--4.50--6.06--6.47--6.47-
Price-to-Total Gains Ratio-7.88--2,668.39-17.56--629.82--629.82-
Price to Book Ratio0.91-2.00-2.68-2.72-2.72-
Price-to-Total Gains Ratio-7.88--2,668.39-17.56--629.82--629.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.956476
Number of shares111
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.250.16
Usd Total Gains Per Share-0.250.16
Gains per Quarter (111 shares)-28.2218.28
Gains per Year (111 shares)-112.8773.11
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-113-12307363
20-226-2360146136
30-339-3490219209
40-451-4620292282
50-564-5750366355
60-677-6880439428
70-790-8010512501
80-903-9140585574
90-1016-10270658647
100-1129-11400731720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.017.00.00.0%0.017.00.00.0%0.017.00.00.0%
Book Value Change Per Share0.04.00.00.0%4.08.00.033.3%7.010.00.041.2%7.010.00.041.2%7.010.00.041.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%7.010.00.041.2%7.010.00.041.2%7.010.00.041.2%

Fundamentals of Altimmune

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Fundamental data was last updated by Penke on 2024-03-27 14:43:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Altimmune Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Altimmune earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Net Profit Margin of -5,710.2% means that €-57.10 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Altimmune Inc:

  • The MRQ is -5,710.2%. The company is making a huge loss. -2
  • The TTM is -87,323.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-5,710.2%TTM-87,323.3%+81,613.1%
TTM-87,323.3%YOY-372,146.3%+284,823.0%
TTM-87,323.3%5Y-110,878.5%+23,555.2%
5Y-110,878.5%10Y-110,878.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,710.2%-159.2%-5,551.0%
TTM-87,323.3%-202.3%-87,121.0%
YOY-372,146.3%-263.0%-371,883.3%
5Y-110,878.5%-452.4%-110,426.1%
10Y-110,878.5%-589.0%-110,289.5%
1.1.2. Return on Assets

Shows how efficient Altimmune is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • -12.4% Return on Assets means that Altimmune generated €-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Altimmune Inc:

  • The MRQ is -12.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.4%TTM-10.6%-1.8%
TTM-10.6%YOY-10.1%-0.5%
TTM-10.6%5Y-10.3%-0.3%
5Y-10.3%10Y-10.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.4%-12.5%+0.1%
TTM-10.6%-12.2%+1.6%
YOY-10.1%-11.2%+1.1%
5Y-10.3%-13.3%+3.0%
10Y-10.3%-14.6%+4.3%
1.1.3. Return on Equity

Shows how efficient Altimmune is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • -13.7% Return on Equity means Altimmune generated €-0.14 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Altimmune Inc:

  • The MRQ is -13.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.7%TTM-11.7%-2.0%
TTM-11.7%YOY-11.1%-0.7%
TTM-11.7%5Y-11.7%-0.1%
5Y-11.7%10Y-11.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.7%-16.0%+2.3%
TTM-11.7%-15.8%+4.1%
YOY-11.1%-13.9%+2.8%
5Y-11.7%-18.2%+6.5%
10Y-11.7%-19.1%+7.4%

1.2. Operating Efficiency of Altimmune Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Altimmune is operating .

  • Measures how much profit Altimmune makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • An Operating Margin of -6,226.5% means the company generated €-62.27  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Altimmune Inc:

  • The MRQ is -6,226.5%. The company is operating very inefficient. -2
  • The TTM is -71,337.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,226.5%TTM-71,337.2%+65,110.6%
TTM-71,337.2%YOY-389,922.9%+318,585.8%
TTM-71,337.2%5Y-110,976.5%+39,639.4%
5Y-110,976.5%10Y-110,976.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,226.5%-299.5%-5,927.0%
TTM-71,337.2%-208.5%-71,128.7%
YOY-389,922.9%-280.2%-389,642.7%
5Y-110,976.5%-459.9%-110,516.6%
10Y-110,976.5%-596.9%-110,379.6%
1.2.2. Operating Ratio

Measures how efficient Altimmune is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 63.27 means that the operating costs are €63.27 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Altimmune Inc:

  • The MRQ is 63.265. The company is inefficient in keeping operating costs low. -1
  • The TTM is 973.407. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ63.265TTM973.407-910.142
TTM973.407YOY3,886.257-2,912.850
TTM973.4075Y1,168.313-194.906
5Y1,168.31310Y1,168.3130.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ63.2652.817+60.448
TTM973.4073.181+970.226
YOY3,886.2573.609+3,882.648
5Y1,168.3135.554+1,162.759
10Y1,168.3137.396+1,160.917

1.3. Liquidity of Altimmune Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Altimmune is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.89 means the company has €12.89 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Altimmune Inc:

  • The MRQ is 12.886. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.648. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.886TTM12.648+0.237
TTM12.648YOY12.172+0.477
TTM12.6485Y15.710-3.061
5Y15.71010Y15.7100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.8863.987+8.899
TTM12.6484.440+8.208
YOY12.1725.569+6.603
5Y15.7106.158+9.552
10Y15.7106.492+9.218
1.3.2. Quick Ratio

Measures if Altimmune is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Quick Ratio of 4.92 means the company can pay off €4.92 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Altimmune Inc:

  • The MRQ is 4.924. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.715. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.924TTM4.715+0.209
TTM4.715YOY2.402+2.313
TTM4.7155Y5.591-0.876
5Y5.59110Y5.5910.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9243.653+1.271
TTM4.7154.158+0.557
YOY2.4025.515-3.113
5Y5.5916.012-0.421
10Y5.5916.206-0.615

1.4. Solvency of Altimmune Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Altimmune assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Altimmune to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Altimmune assets are financed with 9.7% credit (debt) and the remaining percentage (100% - 9.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Altimmune Inc:

  • The MRQ is 0.097. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.098. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.097TTM0.0980.000
TTM0.098YOY0.089+0.009
TTM0.0985Y0.114-0.017
5Y0.11410Y0.1140.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0970.336-0.239
TTM0.0980.330-0.232
YOY0.0890.267-0.178
5Y0.1140.367-0.253
10Y0.1140.378-0.264
1.4.2. Debt to Equity Ratio

Measures if Altimmune is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Altimmune to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.8% means that company has €0.11 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Altimmune Inc:

  • The MRQ is 0.108. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.108. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.108TTM0.108-0.001
TTM0.108YOY0.097+0.011
TTM0.1085Y0.133-0.025
5Y0.13310Y0.1330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1080.376-0.268
TTM0.1080.398-0.290
YOY0.0970.334-0.237
5Y0.1330.431-0.298
10Y0.1330.476-0.343

2. Market Valuation of Altimmune Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Altimmune generates.

  • Above 15 is considered overpriced but always compare Altimmune to the Biotechnology industry mean.
  • A PE ratio of -1.65 means the investor is paying €-1.65 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Altimmune Inc:

  • The EOD is -5.820. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.651. Based on the earnings, the company is expensive. -2
  • The TTM is -4.496. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.820MRQ-1.651-4.169
MRQ-1.651TTM-4.496+2.845
TTM-4.496YOY-6.058+1.562
TTM-4.4965Y-6.474+1.978
5Y-6.47410Y-6.4740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.820-2.697-3.123
MRQ-1.651-2.422+0.771
TTM-4.496-2.709-1.787
YOY-6.058-4.116-1.942
5Y-6.474-6.257-0.217
10Y-6.474-6.478+0.004
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Altimmune Inc:

  • The EOD is -5.872. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.666. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.840. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.872MRQ-1.666-4.206
MRQ-1.666TTM-4.840+3.174
TTM-4.840YOY-8.069+3.229
TTM-4.8405Y-7.350+2.510
5Y-7.35010Y-7.3500.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.872-3.344-2.528
MRQ-1.666-2.939+1.273
TTM-4.840-3.486-1.354
YOY-8.069-5.592-2.477
5Y-7.350-8.464+1.114
10Y-7.350-8.872+1.522
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Altimmune is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.91 means the investor is paying €0.91 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Altimmune Inc:

  • The EOD is 3.200. Based on the equity, the company is fair priced.
  • The MRQ is 0.908. Based on the equity, the company is cheap. +2
  • The TTM is 2.001. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.200MRQ0.908+2.292
MRQ0.908TTM2.001-1.093
TTM2.001YOY2.676-0.675
TTM2.0015Y2.717-0.717
5Y2.71710Y2.7170.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.2002.198+1.002
MRQ0.9082.042-1.134
TTM2.0012.121-0.120
YOY2.6762.907-0.231
5Y2.7173.682-0.965
10Y2.7174.114-1.397
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Altimmune Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.298-0.235-21%-0.018-94%0.152-296%0.152-296%
Book Value Per Share--2.5882.887-10%3.371-23%2.828-8%2.828-8%
Current Ratio--12.88612.648+2%12.172+6%15.710-18%15.710-18%
Debt To Asset Ratio--0.0970.0980%0.089+10%0.114-15%0.114-15%
Debt To Equity Ratio--0.1080.108-1%0.097+11%0.133-19%0.133-19%
Dividend Per Share----0%-0%-0%-0%
Eps---0.356-0.320-10%-0.374+5%-0.302-15%-0.302-15%
Free Cash Flow Per Share---0.353-0.330-6%-0.290-18%-0.284-20%-0.284-20%
Free Cash Flow To Equity Per Share---0.342-0.215-37%0.008-4351%0.132-360%0.132-360%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.715--------
Intrinsic Value_10Y_min---18.495--------
Intrinsic Value_1Y_max---1.426--------
Intrinsic Value_1Y_min---1.401--------
Intrinsic Value_3Y_max---4.857--------
Intrinsic Value_3Y_min---4.625--------
Intrinsic Value_5Y_max---8.976--------
Intrinsic Value_5Y_min---8.282--------
Market Cap444875292.000+72%126209186.100325442663.413-61%488530023.250-74%397249362.935-68%397249362.935-68%
Net Profit Margin---57.102-873.233+1429%-3721.463+6417%-1108.785+1842%-1108.785+1842%
Operating Margin---62.265-713.372+1046%-3899.229+6162%-1109.765+1682%-1109.765+1682%
Operating Ratio--63.265973.407-94%3886.257-98%1168.313-95%1168.313-95%
Pb Ratio3.200+72%0.9082.001-55%2.676-66%2.717-67%2.717-67%
Pe Ratio-5.820-252%-1.651-4.496+172%-6.058+267%-6.474+292%-6.474+292%
Price Per Share8.280+72%2.3496.057-61%9.093-74%7.394-68%7.394-68%
Price To Free Cash Flow Ratio-5.872-252%-1.666-4.840+191%-8.069+384%-7.350+341%-7.350+341%
Price To Total Gains Ratio-27.788-252%-7.883-2668.388+33748%17.557-145%-629.819+7889%-629.819+7889%
Quick Ratio--4.9244.715+4%2.402+105%5.591-12%5.591-12%
Return On Assets---0.124-0.106-15%-0.101-19%-0.103-17%-0.103-17%
Return On Equity---0.137-0.117-15%-0.111-19%-0.117-15%-0.117-15%
Total Gains Per Share---0.298-0.235-21%-0.018-94%0.152-296%0.152-296%
Usd Book Value--150401760.065167789310.364-10%195897877.722-23%164333837.472-8%164333837.472-8%
Usd Book Value Change Per Share---0.322-0.254-21%-0.020-94%0.165-296%0.165-296%
Usd Book Value Per Share--2.7993.123-10%3.646-23%3.059-8%3.059-8%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.385-0.346-10%-0.405+5%-0.327-15%-0.327-15%
Usd Free Cash Flow---20487648.414-19167606.636-6%-16872223.239-18%-14551322.123-29%-14551322.123-29%
Usd Free Cash Flow Per Share---0.381-0.357-6%-0.314-18%-0.307-20%-0.307-20%
Usd Free Cash Flow To Equity Per Share---0.370-0.233-37%0.009-4351%0.142-360%0.142-360%
Usd Market Cap481221603.356+72%136520476.604352031329.013-61%528442926.150-74%429704635.887-68%429704635.887-68%
Usd Price Per Share8.956+72%2.5416.552-61%9.835-74%7.998-68%7.998-68%
Usd Profit---20671654.237-19617120.862-5%-21736268.181+5%-17805871.656-14%-17805871.656-14%
Usd Revenue--362011.45769752.208+419%829940.767-56%831565.259-56%831565.259-56%
Usd Total Gains Per Share---0.322-0.254-21%-0.020-94%0.165-296%0.165-296%
 EOD+5 -3MRQTTM+11 -22YOY+10 -235Y+8 -2510Y+8 -25

3.2. Fundamental Score

Let's check the fundamental score of Altimmune Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.820
Price to Book Ratio (EOD)Between0-13.200
Net Profit Margin (MRQ)Greater than0-57.102
Operating Margin (MRQ)Greater than0-62.265
Quick Ratio (MRQ)Greater than14.924
Current Ratio (MRQ)Greater than112.886
Debt to Asset Ratio (MRQ)Less than10.097
Debt to Equity Ratio (MRQ)Less than10.108
Return on Equity (MRQ)Greater than0.15-0.137
Return on Assets (MRQ)Greater than0.05-0.124
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Altimmune Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.957
Ma 20Greater thanMa 509.254
Ma 50Greater thanMa 1009.090
Ma 100Greater thanMa 2007.525
OpenGreater thanClose7.910
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets166,573
Total Liabilities16,176
Total Stockholder Equity150,397
 As reported
Total Liabilities 16,176
Total Stockholder Equity+ 150,397
Total Assets = 166,573

Assets

Total Assets166,573
Total Current Assets152,964
Long-term Assets13,609
Total Current Assets
Cash And Cash Equivalents 86,855
Short-term Investments 53,924
Net Receivables 4,529
Other Current Assets 241
Total Current Assets  (as reported)152,964
Total Current Assets  (calculated)145,549
+/- 7,415
Long-term Assets
Property Plant Equipment 765
Long-term Assets Other 425
Long-term Assets  (as reported)13,609
Long-term Assets  (calculated)1,190
+/- 12,419

Liabilities & Shareholders' Equity

Total Current Liabilities11,871
Long-term Liabilities4,305
Total Stockholder Equity150,397
Total Current Liabilities
Accounts payable 3,046
Total Current Liabilities  (as reported)11,871
Total Current Liabilities  (calculated)3,046
+/- 8,825
Long-term Liabilities
Other Liabilities 4,002
Long-term Liabilities  (as reported)4,305
Long-term Liabilities  (calculated)4,002
+/- 303
Total Stockholder Equity
Common Stock5
Other Stockholders Equity -5,124
Total Stockholder Equity (as reported)150,397
Total Stockholder Equity (calculated)-5,119
+/- 155,516
Other
Capital Stock5
Common Stock Shares Outstanding 52,859
Net Invested Capital 150,397
Net Tangible Assets 137,978
Net Working Capital 141,093



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
56,388
54,058
54,233
102,544
232,995
245,115
264,251
257,261
236,907
218,865
205,660
209,906
225,277
206,928
187,083
183,316
166,573
166,573183,316187,083206,928225,277209,906205,660218,865236,907257,261264,251245,115232,995102,54454,23354,05856,388
   > Total Current Assets 
41,624
39,395
39,637
87,970
218,132
230,257
245,192
238,625
218,263
204,126
191,093
195,504
211,004
192,813
173,111
169,532
152,964
152,964169,532173,111192,813211,004195,504191,093204,126218,263238,625245,192230,257218,13287,97039,63739,39541,624
       Cash And Cash Equivalents 
10,972
8,963
11,275
64,742
143,495
115,918
149,932
174,102
174,864
190,301
179,947
135,858
127,465
111,097
104,690
102,352
86,855
86,855102,352104,690111,097127,465135,858179,947190,301174,864174,102149,932115,918143,49564,74211,2758,96310,972
       Short-term Investments 
28,226
28,277
21,644
15,484
63,283
100,006
76,575
43,724
25,021
0
0
48,898
74,362
73,783
61,039
57,602
53,924
53,92457,60261,03973,78374,36248,8980025,02143,72476,575100,00663,28315,48421,64428,27728,226
       Net Receivables 
1,012
1,650
5,984
6,689
10,010
12,373
12,699
11,351
11,050
5,838
6,073
6,095
4,353
2,541
252
3,715
4,529
4,5293,7152522,5414,3536,0956,0735,83811,05011,35112,69912,37310,0106,6895,9841,6501,012
       Other Current Assets 
34
34
34
34
34
34
34
34
34
34
34
34
34
34
3,978
241
241
2412413,9783434343434343434343434343434
   > Long-term Assets 
14,764
14,663
14,596
14,573
14,864
14,858
19,059
18,636
18,644
14,739
14,567
14,402
14,273
14,115
13,972
13,784
13,609
13,60913,78413,97214,11514,27314,40214,56714,73918,64418,63619,05914,85814,86414,57314,59614,66314,764
       Property Plant Equipment 
1,880
1,803
1,744
1,687
1,982
1,961
6,064
5,578
5,562
2,246
2,087
1,937
1,172
1,081
1,007
882
765
7658821,0071,0811,1721,9372,0872,2465,5625,5786,0641,9611,9821,6871,7441,8031,880
       Intangible Assets 
12,742
12,732
12,738
12,786
12,795
12,824
12,879
12,956
12,994
12,419
12,419
0
0
12,419
0
0
0
00012,4190012,41912,41912,99412,95612,87912,82412,79512,78612,73812,73212,742
       Other Assets 
142
129
115
101
87
73
115
102
88
74
61
46
33
19
0
0
1
1001933466174881021157387101115129142
> Total Liabilities 
7,004
8,538
12,337
23,022
33,289
19,239
17,813
15,983
27,643
19,730
20,792
15,371
20,248
21,635
19,351
15,602
16,176
16,17615,60219,35121,63520,24815,37120,79219,73027,64315,98317,81319,23933,28923,02212,3378,5387,004
   > Total Current Liabilities 
2,467
3,923
6,045
4,917
6,294
12,020
9,824
9,096
19,127
18,276
19,124
13,845
15,742
17,054
14,951
11,437
11,871
11,87111,43714,95117,05415,74213,84519,12418,27619,1279,0969,82412,0206,2944,9176,0453,9232,467
       Short Long Term Debt 
105
0
0
632
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000063200105
       Accounts payable 
50
18
930
195
875
612
418
1,421
6
2,034
2,205
2,872
1,419
4,804
5,238
4,035
3,046
3,0464,0355,2384,8041,4192,8722,2052,03461,4214186128751959301850
       Other Current Liabilities 
20
62
48
34
20
20
20
58
20
6,090
4,310
0
1,169
1,169
0
56
0
05601,1691,16904,3106,090205820202034486220
   > Long-term Liabilities 
4,537
4,615
6,291
18,105
26,996
7,218
7,989
6,887
8,516
1,454
1,668
1,526
4,506
4,581
4,400
4,165
4,305
4,3054,1654,4004,5814,5061,5261,6681,4548,5166,8877,9897,21826,99618,1056,2914,6154,537
       Capital Lease Obligations Min Short Term Debt
1,805
1,744
1,682
1,618
1,889
1,825
1,740
1,651
1,632
1,535
1,437
1,335
1,230
1,124
1,015
903
788
7889031,0151,1241,2301,3351,4371,5351,6321,6511,7401,8251,8891,6181,6821,7441,805
       Long-term Liabilities Other 
2,975
2,870
4,615
16,500
25,185
5,500
6,365
5,610
7,285
1,454
652
622
3,718
4,581
3,848
4,165
4,305
4,3054,1653,8484,5813,7186226521,4547,2855,6106,3655,50025,18516,5004,6152,8702,975
> Total Stockholder Equity
49,384
45,520
41,897
79,522
199,706
225,876
246,437
241,278
209,264
199,135
184,868
194,535
205,029
185,293
167,732
167,714
150,397
150,397167,714167,732185,293205,029194,535184,868199,135209,264241,278246,437225,876199,70679,52241,89745,52049,384
   Common Stock
2
2
2
3
3
4
4
4
4
4
4
5
5
5
0
5
5
55055544444433222
   Retained Earnings Total Equity00000000000000000
   Accumulated Other Comprehensive Income 00000000000000000
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000
   Other Stockholders Equity -5,124-5,1800-5,227-5,303-5,160-5,040-5,040-5,040-5,038-5,039-5,045-5,042-5,032-5,053-5,020-5,021



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue279
Cost of Revenue--
Gross Profit-279
 
Operating Income (+$)
Gross Profit-
Operating Expense-85,679
Operating Income-85,400-85,679
 
Operating Expense (+$)
Research Development68,069
Selling General Administrative17,610
Selling And Marketing Expenses-
Operating Expense85,67985,679
 
Net Interest Income (+$)
Interest Income6,855
Interest Expense-150
Other Finance Cost-300
Net Interest Income7,005
 
Pretax Income (+$)
Operating Income-85,400
Net Interest Income7,005
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-78,466-85,329
EBIT - interestExpense = -150
-78,466
-78,316
Interest Expense150
Earnings Before Interest and Taxes (EBIT)--78,316
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-78,466
Tax Provision-0
Net Income From Continuing Ops-78,466-78,466
Net Income-78,466
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-71-7,005
 

Technical Analysis of Altimmune
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Altimmune. The general trend of Altimmune is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Altimmune's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Altimmune Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 13.70 < 14.23 < 15.99.

The bearish price targets are: 7.446 > 4.878 > 3.961.

Tweet this
Altimmune Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Altimmune Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Altimmune Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Altimmune Inc. The current macd is -0.37041921.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Altimmune price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Altimmune. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Altimmune price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Altimmune Inc Daily Moving Average Convergence/Divergence (MACD) ChartAltimmune Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Altimmune Inc. The current adx is 12.29.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Altimmune shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Altimmune Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Altimmune Inc. The current sar is 10.05.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Altimmune Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Altimmune Inc. The current rsi is 44.96. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Altimmune Inc Daily Relative Strength Index (RSI) ChartAltimmune Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Altimmune Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Altimmune price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Altimmune Inc Daily Stochastic Oscillator ChartAltimmune Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Altimmune Inc. The current cci is -98.6876359.

Altimmune Inc Daily Commodity Channel Index (CCI) ChartAltimmune Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Altimmune Inc. The current cmo is -13.30217171.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Altimmune Inc Daily Chande Momentum Oscillator (CMO) ChartAltimmune Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Altimmune Inc. The current willr is -57.36377025.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Altimmune is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Altimmune Inc Daily Williams %R ChartAltimmune Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Altimmune Inc.

Altimmune Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Altimmune Inc. The current atr is 0.65153961.

Altimmune Inc Daily Average True Range (ATR) ChartAltimmune Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Altimmune Inc. The current obv is 53,247.

Altimmune Inc Daily On-Balance Volume (OBV) ChartAltimmune Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Altimmune Inc. The current mfi is 12.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Altimmune Inc Daily Money Flow Index (MFI) ChartAltimmune Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Altimmune Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-20 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-21 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-22 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-11-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-11-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-06 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-08 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-21 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-25 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-26 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Altimmune Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Altimmune Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.957
Ma 20Greater thanMa 509.254
Ma 50Greater thanMa 1009.090
Ma 100Greater thanMa 2007.525
OpenGreater thanClose7.910
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Altimmune with someone you think should read this too:
  • Are you bullish or bearish on Altimmune? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Altimmune? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Altimmune Inc

I send you an email if I find something interesting about Altimmune Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Altimmune Inc.

Receive notifications about Altimmune Inc in your mailbox!